Phase III Population Pharmacokinetics And Pharmacodynamics Of Azimilide

Authors: Phillips L, Thompson GA, Grasela TH, Agnew JR
Conference: AAPS
Keywords: adult, antiarrhythmic, atrial fibrillation, cardiology, cardiovascular agents, Emax, flutter, metabolic clearance, NONMEM, paroxysmal supraventricular tachycardia, PK/PD, placebo, potassium, PSVT, QT, QTc, steady state
Division: Cognigen

Purpose

Azimilide (AZ) is a class III antiarrhythmic drug being developed for the treatment of symptomatic atrial fibrillation/flutter (AF/FL) and/or symptomatic paroxysmal supraventricular tachycardia (PSVT). The objectives of this analysis were to develop and validate a population pharmacokinetic (PK) and pharmacodynamic (PD) model.

American Association of Pharmaceutical Scientists (AAPS); New Orleans, Louisiana; November 1999

By Luann Phillips, G.A. Thompson, Thaddeus H. Grasela, and J.R. Agnew